×
About 2,940 results

ALLMedicine™ Von Willebrand Disease Center

Research & Reviews  1,002 results

Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in Von Willebrand di...
https://doi.org/10.1182/blood.2022018956
Blood Roullet S, Luc N et. al.

Mar 18th, 2023 - The lack of innovation in Von Willebrand disease (VWD) originates from many factors including the complexity and heterogeneity of the disease but also from a lack of recognition of the impact of the bleeding symptoms experienced by VWD patients. R...

Building the foundation for a community-generated national research blueprint for inher...
https://doi.org/10.1080/17474086.2023.2171983
Expert Review of Hematology; Sidonio RF, Bryant PC et. al.

Mar 16th, 2023 - Excessive or abnormal mucocutaneous bleeding (MCB) may impact all aspects of the physical and psychosocial wellbeing of those who live with it (PWMCB). The evidence base for the optimal diagnosis and management of disorders such as inherited plate...

The National Hemophilia Foundation State of the Science Research Summit initiative: exe...
https://doi.org/10.1080/17474086.2023.2181782
Expert Review of Hematology; Valentino LA, Witkop ML et. al.

Mar 16th, 2023 - The National Hemophilia Foundation State of the Science Research Summit initiative sought to unify research efforts in the US inherited bleeding disorders (BDs) community around key topics of importance to people living with inherited BDs, the liv...

Switch to pdVWF:pdFVIII concentrate for prophylaxis in a paediatric patient with Type 3...
https://doi.org/10.1080/16078454.2023.2186332
Hematology (Amsterdam, Netherlands); Berger C, Thouvenin S et. al.

Mar 10th, 2023 - To report the long-term prophylaxis management of a child with type 3 von Willebrand disease by switching to Wilate (Octapharma AG), a plasma-derived, double virus-inactivated concentrate of freeze-dried of a 1 to 1 ratio of active Von Willebrand ...

Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
https://clinicaltrials.gov/ct2/show/NCT02472665

Mar 8th, 2023 - This is a multicenter, prospective, open-label, and single-arm study. The study population is planned to include 8 pediatric subjects (<6 years of age) with severe (type 2 or 3) hereditary VWD without inhibitors and with no active bleeding at the ...

see more →

Guidelines  4 results

No. 163-Gynaecological and Obstetric Management of Women With Inherited Bleeding Disord...
https://doi.org/10.1016/j.jogc.2017.11.036
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Demers C, Derzko C et. al.

Feb 16th, 2018 - The prevalence of bleeding disorders, notably von Willebrand disease (vWD), among adult women with objectively documented menorrhagia is consistently reported to be 10% to 20% and is even higher in adolescents presenting with menorrhagia. Diagnost...

Evidence-based recommendations on the treatment of von Willebrand disease in Italy.
https://doi.org/10.2450/2008.0052-08
Blood Transfusion = Trasfusione Del Sangue; Mannucci PM, Franchini M et. al.

Jun 9th, 2009 - von Willebrand disease (VWD) is the most common hereditary bleeding disorder affecting both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes bleeding of mucous membranes and soft tissu...

Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHL...
https://doi.org/10.1002/ajh.21405
American Journal of Hematology; Nichols WL, Rick ME et. al.

May 6th, 2009 - Von Willebrand factor (VWF) mediates blood platelet adhesion and accumulation at sites of blood vessel injury, and also carries coagulation factor VIII (FVIII) that is important for generating procoagulant activity. Von Willebrand disease (VWD), t...

von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the N...
https://doi.org/10.1111/j.1365-2516.2007.01643.x
Haemophilia : the Official Journal of the World Federatio... Nichols WL, Hultin MB et. al.

Mar 5th, 2008 - von Willebrand disease (VWD) is a commonly encountered inherited bleeding disorder affecting both males and females, causing mucous membrane and skin bleeding symptoms, and bleeding with surgical or other haemostatic challenges. VWD may be disprop...

see more →

Drugs  21 results see all →

Clinicaltrials.gov  71 results

Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
https://clinicaltrials.gov/ct2/show/NCT02472665

Mar 8th, 2023 - This is a multicenter, prospective, open-label, and single-arm study. The study population is planned to include 8 pediatric subjects (<6 years of age) with severe (type 2 or 3) hereditary VWD without inhibitors and with no active bleeding at the ...

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age
https://clinicaltrials.gov/ct2/show/NCT04953884

Mar 7th, 2023 - The WIL-33 study aims to determine the efficacy, pharmacokinetics, immunogenicity and safety of wilate as routine prophylaxis in up to 12 paediatric patients (eight evaluable) with severe von Willebrand Disease VWD (defined as screening von Willeb...

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT05500807

Mar 1st, 2023 - Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. VWD currently has few th...

A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers
https://clinicaltrials.gov/ct2/show/NCT05695560

Feb 15th, 2023 - This study is a non-interventional, prospective, qualitative survey to know the unmet needs of participants living with VWD and their caregivers. The study will enroll approximately 49 patients, taking into scope both the participant's and caregiv...

Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
https://clinicaltrials.gov/ct2/show/NCT04477837

Feb 8th, 2023 - Patients will be treated as standard of care, no randomization schedule, no blinded investigational product (IP). The decision which DOAC will be given is made before the subject will enter the trial. The DOAC has to be taken at least for seven da...

see more →

News  69 results

FDA Approves Weekly Factor Therapy for Hemophilia A
https://www.medpagetoday.com/hematologyoncology/hemophilia/103246

Feb 23rd, 2023 - The FDA has approved the recombinant antihemophilic factor Fc-VWF-XTEN fusion protein-ehtl (Altuviiio) for the treatment of adults and children with hemophilia A, Sanofi announced on Thursday. The first-in-class factor VIII replacement therapy car...

Management considerations for women with von Willebrand disease
https://www.mdedge.com/obgyn/article/256915/obstetrics/management-considerations-women-von-willebrand-disease
Andrew M. Kaunitz, MD, NCMP, Andra H. James, MD, MPH

Aug 9th, 2022 - Von Willebrand disease (VWD) represents the most common inherited bleeding disorder, with a prevalence of approximately 1 in 1,000 people. Type 1 disease, associated with a quantitative reduction in von Willebrand factor (VWF), is the most common.

Women with von Willebrand disease: Managing menstrual and postpartum bleeding
https://www.mdedge.com/hematology-oncology/article/252066/bleeding-disorders/women-von-willebrand-disease-managing
Heidi Splete

Feb 23rd, 2022 - Hormonal therapy remains the most effective strategy for managing heavy menstrual bleeding in women with von Willebrand disease, based on data from one of three systematic reviews. Women with von Willebrand disease (VWD) experience many obstetric.

Infusion shown effective for acquired von Willebrand disease
https://www.mdedge.com/hematology-oncology/article/244070/bleeding-disorders/infusion-shown-effective-acquired-von
Mark S. Lesney, PhD

Aug 10th, 2021 - Acquired von Willebrand disease (aVWD) is a rare and serious condition associated with lymphoproliferative disorders, malignancy, autoimmune disorders, and cardiovascular disease. It is most commonly caused by monoclonal gammopathy of undetermined.

Novel molecule prolongs half-life of bleeding disorder treatments
https://www.mdedge.com/hematology-oncology/article/241963/bleeding-disorders/novel-molecule-prolongs-half-life-bleeding
Neil Osterweil

Jun 23rd, 2021 - A novel therapeutic approach using aptamers – short single strands of DNA or RNA designed to selectively bind to a target – shows promise for treating von Willebrand Disease (VWD), and other congenital bleed disorders such as hemophilia A, investi.

see more →

Patient Education  9 results see all →